Volume 5.03 | Jan 24

Mammary Cell News 5.03 January 24, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
BRCA1 Loss Activates Cathepsin L-Mediated Degradation of 53BP1 in Breast Cancer Cells
Researchers demonstrated that BRCA1 loss activates cathepsin L-mediated degradation of 53BP1. Activation of this pathway rescued homologous recombination repair and allowed BRCA1-deficient cells to bypass growth arrest. [J Cell Biol] Abstract | Press Release

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
PUBLICATIONS (Ranked by impact factor of the journal)


Pro-Oncogenic Factors miR-23b- and miR-27b Are Regulated by Her2/Neu, EGF, and TNFα in Breast Cancer
Scientists identified microRNA (miR)-23b and miR-27b as miRNAs that are highly upregulated in human breast cancer. They found that engineered knockdown of miR-23b and miR-27b substantially repressed breast cancer growth. [Cancer Res] Abstract | Press Release

The Mitotic Kinase Aurora-A Promotes Distant Metastases by Inducing Epithelial-to-Mesenchymal Transition in ERα+ Breast Cancer Cells
Researchers demonstrated that constitutive activation of Raf-1 oncogenic signaling induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the transition from an epithelial to a highly invasive mesenchymal phenotype in estrogen receptor α-positive (ERα+) breast cancer cells. [Oncogene] Abstract

Chromatin Effector Pygo2 Regulates Mammary Tumor Initiation and Heterogeneity in MMTV-Wnt1 Mice
Investigators showed that epithelia-specific ablation of Pygopus 2 (Pygo2) in MMTV-Wnt1 transgenic mice results in delayed mammary ductal elongation, but the hyperbranching phenotype, aberrant accumulation of stem/progenitor-like cells, and canonical Wnt signaling output are largely unaffected. [Oncogene] Abstract

The Prognostic Significance and Value of Cyclin D1, CDK4 and p16 in Human Breast Cancer
The material consisted of 102 formalin-fixed human breast cancer samples, in which cyclin D1, CDK4 and p16 expression was evaluated immunohistochemically. The amounts of cyclin D1 mRNA present were analyzed by quantitative real time PCR. [Breast Cancer Res] Abstract | Full Article

Loss of E-Cadherin Is Not a Necessity for Epithelial to Mesenchymal Transition in Human Breast Cancer
Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a spindle cell morphology in combination with loss of E-cadherin and upregulation of mesenchymal markers. However, by studying E-cadherin inactivation in 38 human breast cancer cell lines, the authors noted that not all cell lines that had undergone EMT had concomitantly lost E-cadherin expression. [Breast Cancer Res Treat] Abstract

Involvement of Early Growth Response Factors in TNFα-Induced Aromatase Expression in Breast Adipose
Scientists showed that the early growth response (Egr) transcription factors play an important role in the TNFα-induced signaling pathway resulting in elevated distal promoter I.4 transcription. TNFα treatment of breast adipose fibroblasts increases mRNA levels of all four Egr family members, with EGR2 being the most highly expressed. [Breast Cancer Res Treat] Abstract

The Heterochronic MicroRNA let-7 Inhibits Cell Motility by Regulating the Genes in the Actin Cytoskeleton Pathway in Breast Cancer
Researchers report that the expression levels of three let-7 family members, let-7a, let-7b, and let-7g, were significantly decreased in breast cancer patients with lymph node metastasis compared to those without lymph node metastasis. [Mol Cancer Res] Abstract


Persistence in Patients with Breast Cancer Treated with Tamoxifen or Aromatase Inhibitors: A Retrospective Database Analysis
Researchers analyzed the persistence with tamoxifen and aromatase inhibitors in postmenopausal women with hormone-receptor-positive breast cancer and identified determinants of non-persistence. [Breast Cancer Res Treat] Abstract

Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers
Patients with stage I to stage IIIC, human epidermal growth factor receptor 2-negative (HER2) breast cancer were randomly assigned to receive either docetaxel followed by capecitabine or docetaxel administered concomitantly with capecitabine. [Clin Breast Cancer] Abstract

Free Wallchart | Assays for Human Mammary Stem and Progenitor Cells

Metals and Breast Cancer
The authors address the current understanding of the mechanism by which cadmium and bivalent cationic metals activate estrogen receptor-α. They also summarize the in vitro and in vivo evidence that cadmium functions as an estrogen and the potential role of cadmium in breast cancer. [J Mammary Gland Biol Neoplasia] Abstract

Lorus Therapeutics Announces Issuance of United States Patent for Cancer Therapy IL-17E
Lorus Therapeutics Inc. announced that the United States Patent and Trademark Office has issued Lorus’ patent for its novel cancer therapy IL-17E. The US patent protects methods of treating cancer with IL-17E, both alone and in combination with anticancer therapy drugs including gemcitabine, paclitaxel, docetaxel, erlotinib, cisplatin, and bevacizumab. The patent covers the treatment of a wide range of cancers, including breast, lung, colon, pancreatic, gastric and ovarian tumors, as well as melanoma. [Lorus Therapeutics Inc.] Press Release

Northwestern Medicine Plans $1 Billion Research Investment
Leaders of Northwestern Medicine, comprising Northwestern University Feinberg School of Medicine, Northwestern Medical Faculty Foundation and Northwestern Memorial HealthCare, announced they have made a transformational commitment of more than $1 billion toward creating a leading medical research enterprise on Northwestern’s campus in Chicago’s Streeterville neighborhood. [Northwestern University] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW The 1st Annual World Congress of Geriatrics and Gerontology 2013 (WCGG-2013)
October 12, 2013
Dalian, China

our events page to see a complete list of events in the mammary cell community.


Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Postdoctoral Position/PhD Student – Resistance to Anti-Cancer Drug Therapy (The Netherlands Cancer Institute)

Laboratory Technician/Manager Position – MicroRNA Cancer Biology (Thomas Jefferson University)

Postdoctoral Position –  Impact of Ubiquitin-Proteasome Pathway in Genome Stability and Breast Cancer (University of Pittsburgh)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Bioinformatics Position in Cancer Research (San Raffaele Scientific Institute)

Postdoctoral Research Assistant – Clonal Expansion and Progression of Ductal Carcinoma In Situ (Barts Cancer Institute)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us